US-based ElectroCore has reported a positive outcome from the Event study conducted on non-invasive Gammacore vagus nerve stimulation (nVNS) therapy in treating patients with chronic migraine.

Gammacore involves a non-invasive procedure where a hand-held device issues an electrical signal.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

A conductive gel is applied on the stimulation surfaces of the device which is then placed on the neck.

"Our trial suggests that nVNS is a safe and effective alternative to drug therapies."

The dosage takes about two minutes to be administered.

The initial two months of the comparative phase of the sham-controlled pilot study subjected patients to Gammacore nVNS who were compared to those using a sham device.

Study results have noted a 1.9 decrease in headache per 28 days in three nVNS treated patients.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

During the next phase, the occurrence of headache continued to decrease as it was revealed that patients who remained on the nVNS therapy for longer periods experienced an increased drop in headaches.

The therapy is believed to be safe, tolerable and a cost-effective alternative to the currently approved medication for chronic migraine.

Jefferson Headache Center director Jefferson Medical College Professor of neurology and EVENT study lead author Stephen Silberstein said: "In this pilot study we showed that nVNS was able to demonstrate a progressively more meaningful decrease in headache days in those patients who were treated with nVNS for a number of months.

“Our trial suggests that nVNS is a safe and effective alternative to drug therapies.

“I look forward to participating in larger studies in migraine with the gammaCore nVNS therapy to further confirm and expand on these findings."

ElectroCore has initiated two new large studies to evaluate the effect of nVNS in the prevention and treatment of migraine.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Awarded for Innovation in Remote Hearing Diagnostics , hearX’s Self Test Kit (STK) delivers clinically validated audiometry via smart devices, enabling remote, scalable hearing assessments in homes, clinics and retail. Learn how hearX is redefining hearing care delivery and reducing costs for providers globally.

Discover the Impact